CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response - Wikidata - wikimedia - TriplyDB

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

http://www.wikidata.org/entity/Q37386855

about

Is personalized medicine achievable in obstetrics?Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.Pharmacogenomics: application to the management of cardiovascular disease Cardiovascular pharmacogenomics A case for pharmacogenomics in management of cardiac arrhythmias.Autonomic and hemodynamic origins of pre-hypertension: central role of heredity.The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.Gene-environment interactions of selected pharmacogenes in arterial hypertension.An update on the pharmacogenetics of treating hypertension.CACNA1C polymorphisms Impact Cognitive Recovery in Patients with Bipolar Disorder in a Six-week Open-label Trial.Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function.Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.Voltage-gated calcium channels: Novel targets for cancer therapy.Does the bipolar disorder-associated CACNA1C gene confer susceptibility to schizophrenia in Han Chinese?A gain-of-function SNP in TRPC4 cation channel protects against myocardial infarction.

P2860

Q26864177-C3A8437B-75E3-4F69-910B-EFC62C45C64E Q34978296-84A0025D-366A-4BE1-B955-1313CECBFC01 Q35309161-38064559-67D2-4D19-BB67-E6A1DAE55364 Q35447163-4B350E11-31C8-4B6B-A9E4-4A1E014B8C2B Q35914690-052260D2-4364-410D-963F-9CBE0444042B Q36030841-71F8CC54-EB79-4129-AF26-0758FCD73CB5 Q36441528-7E06573A-533C-4C2E-A2DC-327665047243 Q37723155-5CD71BBB-FB44-48AB-8CF4-E2CE8A8B3704 Q38066959-4BD0290A-15F3-496D-A32D-BAC51DAAEFB7 Q38263731-0445A194-C053-41F7-B036-1428EABDA47E Q38647923-8052117F-FCB0-4B85-AFA7-087D6EAEB20C Q38732534-98063419-8242-4510-A128-E96CBA32E6D2 Q38846045-9F7D38FD-9108-4D1A-979D-56899C9FEDE0 Q38974781-13779883-9B61-4127-91E4-5AF17D600D77 Q41145371-C8D47B3C-9766-4CC0-BA36-42197E43D6C7 Q45906648-FEC2FA3B-745D-4074-8E10-65B87320EF52 Q46373181-F70EBD7C-DA2B-4921-A5D3-4A912639827B

P2860

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

http://www.wikidata.org/entity/Q37386855

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

@en

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.

@nl

type

label

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

@en

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.

@nl

prefLabel

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

@en

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.

@nl

P1433

Q37386855-5D8B0ACC-EAA3-45D7-8F52-F5CFC2152C2F

P1476

Q37386855-D9145A50-3249-41FC-88E5-A13174531E47

P2093

Q37386855-52D65F05-142D-4067-9A78-E30696943C28

Q37386855-570F3201-93E2-4348-9CCF-53CAF6CC0DDF

Q37386855-8A251CEC-A0A0-4E0B-BEFB-ACBD4CCB37C1

Q37386855-8A9DDF07-27D3-4929-954E-3072336BA8C1

Q37386855-993782EC-65D1-48D8-A49E-DBF5DC4404C3

Q37386855-9FF7B953-93F4-4E19-A9A6-2AAC3D64F2B0

Q37386855-B67B760D-1283-4A70-8DCA-5FA5101C6FBC

Q37386855-BCF34975-946C-44B8-8F4D-A17563E363CF

Q37386855-C0F4B14C-B9EA-478D-92CA-4C706A2AE5A8

Q37386855-EC4B09B3-B6E7-42FA-9307-BCE4E58391ED

P2860

Q37386855-0C191D47-4D78-4F24-87D3-6615BCFF1E3C

Q37386855-3ADB7C5F-B07D-41C6-ADF5-F40A7CA82C4F

Q37386855-459B41E6-36AF-408A-85C3-880A6F434F19

Q37386855-6AC90C84-ABE6-44CC-B166-FA04B761A4E4

Q37386855-A5C6498B-D349-4AC7-92B8-53D585C7388B

Q37386855-AB00A896-468E-448E-A5C3-D7B06CB7B240

Q37386855-B3A6162C-76B4-4DFF-A3F9-A5D96C5C94A5

Q37386855-B4B6FAFC-6081-4475-8026-0E433F726D48

Q37386855-B56B7256-9D74-40DF-BC2F-9B5AD9F76069

Q37386855-D89EF8EC-3BD0-4324-B4CB-449F20D7A82E

P304

Q37386855-478C6654-3313-469B-A446-22781922DA14

P31

Q37386855-738C888E-3677-4E53-BAF0-BBC86083A6B4

P356

Q37386855-5520F568-2140-432E-97A9-90B73A1CE386

P433

Q37386855-910705EA-7E64-4539-964C-26CDC8B0A1AC

P478

Q37386855-79CC18B5-3755-43B2-968D-E9D762F51021

P50

Q37386855-2280EB35-7FA7-488F-9CC2-105874896688

Q37386855-EBC4DB26-97D8-4430-852F-EA402F0B6EFE

P577

Q37386855-4FC39018-B8E4-428B-B403-551757825895

P698

Q37386855-4E71DFB1-7D5B-422B-AAC5-D87FE1F5654B

P921

Q37386855-172E6CEE-3E93-44D2-B069-77448D509C61

P932

Q37386855-83046823-A8D6-4964-8D07-564E0DFCAE39

P356

CIRCGENETICS.109.857839

P1433

Circulation: Cardiovascular Genetics

P1476

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response

@en

P2093

Amber L Beitelshees

http://www.w3.org/2001/XMLSchema#string

Carl J Pepine

http://www.w3.org/2001/XMLSchema#string

Danxin Wang

http://www.w3.org/2001/XMLSchema#string

Hrishikesh Navare

http://www.w3.org/2001/XMLSchema#string

James I Moss

http://www.w3.org/2001/XMLSchema#string

Julie A Johnson

http://www.w3.org/2001/XMLSchema#string

Nicolas J Schork

http://www.w3.org/2001/XMLSchema#string

Rhonda M Cooper-DeHoff

http://www.w3.org/2001/XMLSchema#string

Taimour Y Langaee

http://www.w3.org/2001/XMLSchema#string

Yan Gong

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic structure of human L-type Ca2+ channel

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Calcium-antagonist drugs.

Large-scale SNP analysis reveals clustered and continuous patterns of human genetic variation

Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).

beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.

Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues

KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)

PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis.

Caution on pedigree haplotype inference with software that assumes linkage equilibrium.

P304

362-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCGENETICS.109.857839

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Wessel

P577

2009-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20031608

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2761685

http://www.w3.org/2001/XMLSchema#string